Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This trial tests a combination of four drugs — cladribine, idarubicin, cytarabine (a standard chemotherapy), and quizartinib (a targeted drug for a mutation called FLT3) — for patients with acute myeloid leukemia (AML) or high-risk MDS (a bone marrow disorder that can become leukemia). Two groups are studied: newly diagnosed patients and those whose leukemia came back or didn't respond to treatment. **You may be eligible if...** - You have been diagnosed with AML or high-risk MDS (with more than 10% bone marrow blasts) - For the frontline group: You are 18-65 years old and have not received prior chemotherapy for AML/MDS - For the relapsed group: You are 18 or older and have received prior treatment that is no longer working - You are in reasonably good general health (ECOG performance 0-2) - Your kidneys and liver are functioning adequately **You may NOT be eligible if...** - You have a type of leukemia called acute promyelocytic leukemia (APL) - You have serious uncontrolled infections or significant organ problems - You have active central nervous system leukemia - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.